2023 – year in review

Fitness influencers and physicians raised alarms about risks of finasteride for hair loss this year, reaching millions of people through tweets, videos and podcasts. On the regulatory front, in France boxed warnings were added to finasteride packaging. Health Canada added a warning about suicidality while the UK regulator launched a safety review. Forty-four relevant research … Read more

Finasteride appears on Prescrire’s latest ‘Drugs to Avoid’ list

Prescrire, an independent patient safety organization based in France, has updated its Drugs to Avoid guide. Finasteride appears in the 2024 edition, and has also been included in past editions. The guide notes: Finasteride 1 mg, a 5-alpha reductase inhibitor, has very modest efficacy in androgenic alopecia in men: it increases hair density on the … Read more

2023 – mid-year update

Drug regulators in France and Canada announced new warnings. A popular podcast discussed post-finasteride syndrome, while men’s fitness influencers urged followers to avoid finasteride.

Men’s fitness influencers are raising alarms about finasteride risks

Fitness influencers draw in an audience of younger men who want to be stronger, better-performing, and in some cases more attractive. Some guys worry that hair loss will dim their prospects for dating, sex and relationships—or even professional success. In the era of Instagram, body-hacking and telehealth companies such as Hims and Keeps, young men’s … Read more

A rundown of new bibliographies & research guides

The research base spans many disciplines and goes back almost 50 years. To help researchers get oriented, an on-ramp was added. In the Systems & functions area, a new bibliography was added: Adverse effects on skin, comprising nine case reports. The gynecomastia bibliography has been expanded. The bibliography on the musculoskeletal system has been expanded … Read more

Recent developments

In June 2022, the FDA required the addition of ‘suicidal ideation and behavior’ to the Propecia (finasteride 1 mg) label. In July, France’s national drug regulator ANSM added materials to help patients better understand the risks of finasteride.

FDA quashed internal warning on suicidality linked to Propecia; changed course in 2022

In 2010, Merck requested to add a warning of depression to the Propecia label. A safety group within FDA concurred, but FDA’s dermatology products group did not support the change. Over a decade later, FDA required the addition of ‘suicidal ideation and behavior’ to the Propecia label.